Polyunsaturated fatty acids of the n-3 class in chronic dialysis.
N-3 PUFAs are believed to 1) reduce serum lipids, 2) modify the complement activating system, 3) increase red blood cell elasticity, and 4) decrease thrombotic events. These four parameters were investigated in 19 chronic stabilized dialysis patients assessed by 1) the control of the serum lipids, 2) the degree of leukopenia 10 minutes after the start of dialysis, 3) the degree of red cell fragmentation (RCF) during dialysis, and 4) the reusability of the dialyzer. The patients were their own controls during four periods: 1) no PUFAs for longer than 6 months, 2) 4 x 425 mg of PUFAs/day for 6 weeks, 3) 6 x 425 mg PUFAs/day for 6 weeks, and 4) no PUFAs during at least 6 weeks. Previous diets and medications remained unchanged. It was concluded that there was no significant effect on serum lipids in the given dosages, and no effect on the degree of leukopenia, red blood cell elasticity or bleeding, and/or antithrombotic activity. No change was seen in insulinemia, fibrinogenemia, or arterial pressure. No serious side effects were noted other than a "fishy aftertaste."
Hombrouckx
R O
RO
Dialysis Unit Ronse, Kliniek Hogerlucht, Ronse, Belgium.
Bogaert
A M
AM
Leroy
F M
FM
De Vos
J Y
JY
Vermaercke
N M
NM
Picavet
L M
LM
Larno
L A
LA
D000328:Adult; D000368:Aged; D004907:Erythrocyte Deformability / Q000187:drug effects; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007970:Leukopenia / Q000517:prevention & control; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D013927:Thrombosis / Q000517:prevention & control
D015525:Fatty Acids, Omega-3; D008055:Lipids